CN101287478B - 影响脂肪代谢和肥胖的益生菌 - Google Patents

影响脂肪代谢和肥胖的益生菌 Download PDF

Info

Publication number
CN101287478B
CN101287478B CN2006800368040A CN200680036804A CN101287478B CN 101287478 B CN101287478 B CN 101287478B CN 2006800368040 A CN2006800368040 A CN 2006800368040A CN 200680036804 A CN200680036804 A CN 200680036804A CN 101287478 B CN101287478 B CN 101287478B
Authority
CN
China
Prior art keywords
probiotics
probiotic
product
products
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006800368040A
Other languages
English (en)
Chinese (zh)
Other versions
CN101287478A (zh
Inventor
凯萨·奥尔松
玛吉特·马拉普
乌拉·斯文松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arla Foods AMBA
Original Assignee
Ke Hansen Co ltd
Arla Foods AMBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37943064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101287478(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ke Hansen Co ltd, Arla Foods AMBA filed Critical Ke Hansen Co ltd
Publication of CN101287478A publication Critical patent/CN101287478A/zh
Application granted granted Critical
Publication of CN101287478B publication Critical patent/CN101287478B/zh
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/23—Lactobacillus acidophilus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
    • Y02P60/87—Re-use of by-products of food processing for fodder production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2006800368040A 2005-10-07 2006-10-02 影响脂肪代谢和肥胖的益生菌 Active CN101287478B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0502214A SE529185C2 (sv) 2005-10-07 2005-10-07 Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
SE0502214-0 2005-10-07
PCT/SE2006/001117 WO2007043933A1 (en) 2005-10-07 2006-10-02 Probiotics to influence fat metabolism and obesity

Publications (2)

Publication Number Publication Date
CN101287478A CN101287478A (zh) 2008-10-15
CN101287478B true CN101287478B (zh) 2012-10-03

Family

ID=37943064

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800368040A Active CN101287478B (zh) 2005-10-07 2006-10-02 影响脂肪代谢和肥胖的益生菌

Country Status (16)

Country Link
US (1) US20080267933A1 (enExample)
EP (2) EP2431044B1 (enExample)
JP (1) JP2009511469A (enExample)
CN (1) CN101287478B (enExample)
AU (1) AU2006299956B2 (enExample)
BR (1) BRPI0616993A2 (enExample)
CA (1) CA2624890A1 (enExample)
CY (1) CY1113704T1 (enExample)
DK (2) DK1945235T3 (enExample)
EA (1) EA015461B1 (enExample)
ES (2) ES2396865T3 (enExample)
PL (1) PL1945235T3 (enExample)
PT (1) PT1945235E (enExample)
SE (1) SE529185C2 (enExample)
SI (1) SI1945235T1 (enExample)
WO (1) WO2007043933A1 (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008009726A (es) * 2006-01-27 2009-03-05 Danisco Uso de microorganismos probioticos para el tratamiento y prevencion de la obesidad y trastornos relacionados.
JP5229977B2 (ja) * 2006-09-08 2013-07-03 雪印メグミルク株式会社 血中アディポネクチン濃度増加促進及び／又は減少抑制剤
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
CA2694384A1 (en) * 2007-07-25 2009-01-29 Campina Nederland Holding B.V. Probiotics for inducing satiety and/or satiation
EP2030623A1 (en) * 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
JP5225652B2 (ja) * 2007-10-29 2013-07-03 雪印メグミルク株式会社 アディポネクチン分泌促進及び／又は減少抑制剤
EP2227239A2 (en) * 2007-12-06 2010-09-15 Arla Foods Amba Probiotic bacteria and regulation of fat storage
FR2930264B1 (fr) * 2008-04-18 2013-02-22 Gervais Danone Sa Nouvelle souche de lactobacillus paracasei subsp. paracasei dotee de proprietes antimicrobiennes et immunomodulatrices.
PT2123168E (pt) * 2008-05-16 2012-03-28 Nestec Sa Lactobacillus paracasei e controlo de peso
EP2276344A4 (en) * 2008-05-19 2011-09-14 Nestec Sa METHODS OF LIMITING ABSORPTION OF LIPIDS BY ANIMAL
EP2320889A4 (en) * 2008-08-15 2016-09-21 Nestec Sa METHOD FOR INCREASING THE CHANGE OF ENERGY REPLACEMENT
FR2942719B1 (fr) 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
US8551543B2 (en) * 2009-03-06 2013-10-08 Fédération Des Producteurs Acéricoles Du Québec Symbiotic maple product compositions and methods
EP2407170B1 (en) * 2009-03-10 2015-03-25 Jinis Biopharmaceuticals Co. Prevention and treatment of obesity and metabolic diseases induced by obesity using microorganisms
US20120027737A1 (en) 2009-03-25 2012-02-02 Chr-Hansen A/S Use of probiotics to ameliorate diet-induced insulin resistance
US20120020944A1 (en) * 2009-03-25 2012-01-26 Chr-Hansen A/S Use of a probiotic to regulate body weight
WO2010114864A1 (en) * 2009-04-01 2010-10-07 Little Calumet Holdings, Llc Probiotic oral dosage forms
FI123157B (fi) * 2009-05-12 2012-11-30 Valio Oy Probioottien uusi käyttö
EP3181134B1 (en) * 2009-06-19 2019-10-30 DuPont Nutrition Biosciences ApS Bifidobacteria for treating diabetes and related conditions
JP5436991B2 (ja) * 2009-09-10 2014-03-05 国立大学法人北海道大学 ラクトバチルス・プランタラムの菌体又は培養物を有効成分とするインスリン抵抗性改善剤
EP2308499A1 (en) * 2009-09-30 2011-04-13 Nestec S.A. Bifidobacterium longum ATCC BAA-999 (BL999) and weight control
PL2498789T3 (pl) 2009-11-11 2017-01-31 Alimentary Health Limited Probiotyczny szczep bifidobacterium
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
NL2004200C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides in weight management.
AU2011262840B2 (en) * 2010-06-08 2015-02-05 Asahi Group Holdings, Ltd. Lipid metabolism-improving agent
ES2389547B1 (es) * 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
ITMI20111488A1 (it) 2011-08-03 2013-02-04 Gnosis Spa Formulazioni comprendenti saccharomyces boulardii e superossido dismutasi (sod) per controllare l'obesita'
PH12014500453A1 (en) * 2011-10-18 2020-12-18 Socia‰Ta‰ Des Produits Nestla‰ S A Composition for use in increasing insulin sensitivity and/or reducing insulin resistance
JP2016507216A (ja) 2012-11-12 2016-03-10 コンパニ・ジェルベ・ダノンＣｏｍｐａｇｎｉｅ Ｇｅｒｖａｉｓ Ｄａｎｏｎｅ 体脂肪の蓄積を低減させるためのラクトバチルスラムノサス株
KR20150143803A (ko) 2013-04-17 2015-12-23 산토리 홀딩스 가부시키가이샤 락토바실러스속 균 함유 조성물
ES2526986B1 (es) 2013-07-18 2015-11-02 Biopolis, S.L. Nueva cepa de Bifidobacterium animalis subsp. lactis CECT 8145 y su uso para el tratamiento y/o prevención de sobrepeso y obesidad y enfermedades asociadas
KR101535077B1 (ko) * 2013-09-13 2015-07-08 주식회사한국야쿠르트 인슐린 저항성 개선 효능을 가지는 비피도박테리움 락티스 hy8101 및 이를 유효성분으로 함유하는 제품
KR101545551B1 (ko) 2013-12-12 2015-08-19 주식회사한국야쿠르트 인슐린 저항성 개선 효능을 갖는 7종의 유산균 복합균주를 유효성분으로 함유하는 조성물
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
BR112016018283A2 (pt) * 2014-02-14 2017-08-08 Vesale Pharma Sa Composição que compreende bifidobacterium animalis ssp. lactis
WO2015121458A2 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant du bifidobacterium animalis ssp. lactis
WO2015121455A1 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant au moins un probiotique
BE1000016B1 (fr) * 2014-04-25 2016-02-01 Vesale Pharma Nv Composition comprenant du bifidobacterium animalis ssp. lactis.
BE1000017B1 (fr) * 2014-04-25 2016-01-21 Vesale Pharma Nv Composition comprenant au moins un probiotique
EP3177277B1 (en) * 2014-08-08 2020-03-11 Société des Produits Nestlé S.A. Myo-inositol and probiotics and uses
CN104186655B (zh) * 2014-08-27 2016-06-29 内蒙古伊利实业集团股份有限公司 具有降血脂及抗氧化功能的低脂发酵乳及其制备方法
KR101604212B1 (ko) * 2015-07-17 2016-03-17 울산대학교 산학협력단 Ｎａｄ를 함유하는 비만 또는 내당능장애의 예방 및 치료용 조성물
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
EP3387156B1 (en) * 2015-12-11 2020-04-29 PrecisionBiotics Group Limited Lactobacillus casei for treating obesity and associated metabolic disorders
AU2017249661B2 (en) * 2016-04-14 2020-03-19 International N&H Denmark Aps Bifidobacteria for reducing food, energy and/or fat intake
KR102794442B1 (ko) 2017-02-10 2025-04-09 퍼펙트 (차이나) 씨오., 엘티디 신규한 프로바이오틱스 비피도박테리움 균주
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
TWI640313B (zh) * 2017-08-18 2018-11-11 長庚生物科技股份有限公司 戈氏副擬桿菌用於抑制肥胖之用途
US11291696B2 (en) 2018-04-11 2022-04-05 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11168299B2 (en) 2018-04-11 2021-11-09 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
WO2020055547A2 (en) 2018-08-18 2020-03-19 Seed Health, Inc. Methods and compositions for honey bee health
FR3095761B1 (fr) 2019-05-06 2023-11-10 Lab Attitude Composition nutraceutique pour induire une perte de poids et réduire la graisse abdominale
CN115279380A (zh) 2019-12-27 2022-11-01 佰欧波利斯有限公司 来自双歧杆菌的脂磷壁酸的用途
CN111587952A (zh) * 2020-05-27 2020-08-28 佛山科学技术学院 一种降低家犬体脂沉积的益生菌添加剂
JP7718672B2 (ja) * 2020-12-25 2025-08-05 日清食品株式会社 腸溶コーティング錠
KR102616412B1 (ko) * 2021-07-30 2023-12-21 주식회사 메디오젠 비피도박테리움 애니말리스 락티스 mg741 균주를 포함하는 비만 또는 비알콜성 지방간 예방 또는 치료용 조성물
FR3125945B1 (fr) 2021-08-03 2024-07-12 Setalg Composition pour protéger un microorganisme dans un environnement acide.
KR102445708B1 (ko) 2021-12-02 2022-09-23 일동바이오사이언스(주) 비피도박테리움 락티스 idcc 4301을 포함하는 체지방감소용 조성물
CN118716406A (zh) * 2024-04-30 2024-10-01 卡士乳业(深圳)有限公司 含活性乳双歧杆菌的发酵乳在调节亚健康人群状态中的应用
WO2026132482A1 (en) 2024-12-19 2026-06-25 Biopolis, S.L. Tea extract and bifidobacterium animalis subsp. lactis strain combination

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029833A1 (en) * 1997-12-08 1999-06-17 Arlafoods Amba Strain of bacteria of the species lactobacillus paracasei subsp. paracasei, composition thereof for use in food and product containing said strain
CN1380902A (zh) * 2000-05-17 2002-11-20 株式会社百尼尔 治疗或预防肥胖症和糖尿病的微生物及含有所述微生物的药物组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61109729A (ja) * 1984-11-05 1986-05-28 Advance Res & Dev Co Ltd コレステロ−ル低下剤
JPS61271223A (ja) * 1985-05-24 1986-12-01 Biofuerumin Seiyaku Kk 血中脂質改善剤
JPH0696537B2 (ja) * 1986-05-02 1994-11-30 雪印乳業株式会社 血清コレステロ−ル上昇抑制剤
JP2992945B2 (ja) * 1994-03-11 1999-12-20 カルピス株式会社 ラクトバチルス・アシドフィルス乳酸菌
JPH107577A (ja) * 1996-06-17 1998-01-13 Yakult Honsha Co Ltd 血糖降下剤
US6696057B1 (en) * 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
US6641808B1 (en) * 1999-09-22 2003-11-04 Lacpro Industries, Llc Composition for treatment of obesity
JP2001097870A (ja) * 1999-09-30 2001-04-10 Snow Brand Milk Prod Co Ltd 乳酸菌を利用した胆汁酸の吸着方法
JP2001292728A (ja) 2000-04-13 2001-10-23 Enajikku Kk 肥満防止食品
US6383482B1 (en) * 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
US6963306B2 (en) * 2001-02-02 2005-11-08 Rosum Corp. Position location and data transmission using pseudo digital television transmitters
EP1344458A1 (en) * 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
US6565847B1 (en) * 2002-07-03 2003-05-20 Vitacost.Com, Inc. Thermogenic weight management composition
US20040014403A1 (en) * 2002-07-16 2004-01-22 Oberkampf Brandon L. CMP point of use filtration
US6942857B2 (en) * 2002-08-09 2005-09-13 Bioneer Corporation Microorganisms for preventing and/or treating obesity or diabetes mellitus
EP1624762B1 (en) * 2003-05-22 2007-02-28 Synbiotics AB A probiotic composition comprising at least two lactic acid bacterial strains which are able to colonise the gastrointestinal tracts in combination with having intestinal survival property, intestinal binding property, an infection protection property and a fiber fermenting property
SE0400355D0 (sv) * 2004-02-17 2004-02-17 Synbiotics Ab New synbiotec use
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
EP2227239A2 (en) * 2007-12-06 2010-09-15 Arla Foods Amba Probiotic bacteria and regulation of fat storage

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029833A1 (en) * 1997-12-08 1999-06-17 Arlafoods Amba Strain of bacteria of the species lactobacillus paracasei subsp. paracasei, composition thereof for use in food and product containing said strain
CN1380902A (zh) * 2000-05-17 2002-11-20 株式会社百尼尔 治疗或预防肥胖症和糖尿病的微生物及含有所述微生物的药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine;Åsa Sullivan1, Lisbeth Barkholt2 and Carl Erik Nord1;《Journal of Antimicrobial Chemotherapy》;20030715(第52期);309页 *

Also Published As

Publication number Publication date
DK2431044T3 (en) 2016-04-11
EA015461B1 (ru) 2011-08-30
SE0502214L (sv) 2007-04-08
DK1945235T3 (da) 2013-01-14
WO2007043933A1 (en) 2007-04-19
EP1945235B1 (en) 2012-09-26
EP1945235A1 (en) 2008-07-23
AU2006299956A1 (en) 2007-04-19
ES2396865T3 (es) 2013-02-28
SE529185C2 (sv) 2007-05-22
EA200800913A1 (ru) 2008-10-30
JP2009511469A (ja) 2009-03-19
CN101287478A (zh) 2008-10-15
EP2431044B1 (en) 2016-01-13
US20080267933A1 (en) 2008-10-30
SI1945235T1 (sl) 2013-02-28
AU2006299956B2 (en) 2012-03-15
CY1113704T1 (el) 2016-06-22
PT1945235E (pt) 2013-01-14
CA2624890A1 (en) 2007-04-19
EP2431044A1 (en) 2012-03-21
EP1945235A4 (en) 2009-11-11
BRPI0616993A2 (pt) 2011-07-05
PL1945235T3 (pl) 2013-03-29
ES2567404T3 (es) 2016-04-22

Similar Documents

Publication Publication Date Title
CN101287478A (zh) 影响脂肪代谢和肥胖的益生菌
An et al. Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats
TWI594758B (zh) 包含雙歧桿菌的組合物、其製備方法及其用途
KR102794442B1 (ko) 신규한 프로바이오틱스 비피도박테리움 균주
DK2442814T3 (en) BIFIDOBACTERIA FOR TREATING DIABETES AND RELATED CONDITIONS
CN113151056A (zh) 益生菌组合物、其制备方法和用途
US20120027737A1 (en) Use of probiotics to ameliorate diet-induced insulin resistance
JP2024529268A (ja) ラクトバチルス属の菌株３種を含む組成物、およびその用途
EP3512966A1 (en) Bacteria
CN106852938A (zh) 拟杆菌(Bacteroides)在治疗和预防肥胖相关疾病中的应用
JP2025537795A (ja) リモシラクトバチルス・ムコサエ（Ｌｉｍｏｓｉｌａｃｔｏｂａｃｉｌｌｕｓ ｍｕｃｏｓａｅ）及びＧＬＰ－１増加を必要とする障害
CN118203603A (zh) 一种后生元及其在调节脂代谢方向的应用
Reehana et al. Synbiotics in Nutrition
US20190307802A1 (en) Probiotic compositions including immune modulators
CN106974940B (zh) 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
CN106974939B (zh) 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
CN115998777B (zh) 副干酪乳杆菌207-27的用途
MX2008004578A (en) Probiotics to influence fat metabolism and obesity
WO2025098973A1 (en) Bifidobacterium adolescentis for reducing the release of proinflammatory cytokines
HK1239564A (en) Application of thick-wall fungus probiotics in treatment and prevention of obesity and related diseases
HK1239564A1 (en) Application of thick-wall fungus probiotics in treatment and prevention of obesity and related diseases
HK40001005A (en) Novel probiotics bifidobacteria strains
Cho Investigation of the functionality of probiotic fortified soy beverages: In vitro and in vivo studies
HK1239568A (en) Application of thick-wall fungus probiotics in treatment and prevention of obesity and related diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CHR. HANSEN A/S

Free format text: FORMER OWNER: ARLA FOODS AMBA

Effective date: 20120803

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20120803

Address after: Holm Hess, Denmark

Applicant after: Arla Foods Amba

Address before: Denmark viby

Applicant before: Arla Foods Amba

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP03 Change of name, title or address

Address after: Denmark viby

Patentee after: Arla Foods Amba

Address before: Holm Hess, Denmark

Patentee before: Arla Foods Amba